Graig Suvannavejh
Stock Analyst at Mizuho
(4.22)
# 452
Out of 5,090 analysts
175
Total ratings
56.06%
Success rate
12.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $142.85 | +35.81% | 2 | Dec 2, 2025 | |
| INSM Insmed | Maintains: Outperform | $196 → $256 | $204.72 | +25.05% | 12 | Dec 1, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $38.74 | +18.74% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $82.00 | +21.95% | 1 | Nov 20, 2025 | |
| IMTX Immatics | Maintains: Outperform | $19 → $23 | $10.30 | +123.30% | 4 | Nov 19, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $54 → $56 | $63.65 | -12.01% | 7 | Nov 18, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $32 → $33 | $29.46 | +12.02% | 8 | Nov 13, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $44 → $46 | $36.00 | +27.78% | 3 | Nov 11, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $200 → $202 | $150.09 | +34.59% | 22 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $24 → $19 | $23.81 | -20.20% | 11 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $2.09 | +91.39% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.87 | +3,356.62% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $1.22 | +186.89% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.25 | +122.22% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $12 | $4.18 | +187.08% | 5 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $6.59 | +51.75% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $9.23 | +19.18% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $17.21 | +51.07% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.71 | -45.62% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $38.76 | -14.86% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.54 | +393.51% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $10.50 | +605.10% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $5 | $3.85 | +29.84% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $5.68 | -82.39% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $105.99 | -66.98% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $24.24 | -67.00% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $65.85 | -13.43% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $31.12 | -83.93% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.91 | +281.59% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.02 | +179.44% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $24.09 | +28.71% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $8.00 | +4,650.00% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.96 | +142.35% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $30.80 | +16.88% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $31.59 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.48 | +2,400.00% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $169.76 | -24.60% | 1 | Sep 14, 2020 |
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $142.85
Upside: +35.81%
Insmed
Dec 1, 2025
Maintains: Outperform
Price Target: $196 → $256
Current: $204.72
Upside: +25.05%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $38.74
Upside: +18.74%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $82.00
Upside: +21.95%
Immatics
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $10.30
Upside: +123.30%
Halozyme Therapeutics
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $63.65
Upside: -12.01%
Terns Pharmaceuticals
Nov 13, 2025
Maintains: Outperform
Price Target: $32 → $33
Current: $29.46
Upside: +12.02%
IDEAYA Biosciences
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $36.00
Upside: +27.78%
Axsome Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $150.09
Upside: +34.59%
Apellis Pharmaceuticals
Nov 3, 2025
Maintains: Neutral
Price Target: $24 → $19
Current: $23.81
Upside: -20.20%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $2.09
Upside: +91.39%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.87
Upside: +3,356.62%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $1.22
Upside: +186.89%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.25
Upside: +122.22%
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $4.18
Upside: +187.08%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $6.59
Upside: +51.75%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $9.23
Upside: +19.18%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $17.21
Upside: +51.07%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.71
Upside: -45.62%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $38.76
Upside: -14.86%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.54
Upside: +393.51%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $10.50
Upside: +605.10%
Sep 19, 2024
Downgrades: Neutral
Price Target: $50 → $5
Current: $3.85
Upside: +29.84%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $5.68
Upside: -82.39%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $105.99
Upside: -66.98%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $24.24
Upside: -67.00%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $65.85
Upside: -13.43%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $31.12
Upside: -83.93%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.91
Upside: +281.59%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.02
Upside: +179.44%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $24.09
Upside: +28.71%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $8.00
Upside: +4,650.00%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.96
Upside: +142.35%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $30.80
Upside: +16.88%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $31.59
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.48
Upside: +2,400.00%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $169.76
Upside: -24.60%